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Abstract
Background—Persons with serious mental illnesses (SMI) are more likely to die earlier than the 
general population, primarily due to increased medical burden, particularly from cardiovascular 
disease (CVD). Life Goals Collaborative Care (LG-CC) is designed to improve health outcomes in 
SMI through self-management, care management, and provider support. This single-blind 
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randomized controlled effectiveness study will determine whether patients with SMI receiving 
LG-CC compared to usual care (UC) experience improved physical health in 12 months.
Methods—Patients diagnosed with SMI and at least one CVD risk factor receiving care at a VA 
mental health clinic were randomized to LG-CC or UC. LG-CC included five self-management 
sessions covering mental health symptom management reinforced through healthy behavior 
change; care coordination and health monitoring via a registry, and provider feedback. The 
primary outcome is change in physical health-related quality of life score (VR-12) from baseline 
to 12 months. Secondary outcomes include changes in mental health-related quality of life, CVD 
risk factors (blood pressure, BMI), and physical activity from baseline to 12 months later.
Results—Out of 304 enrolled, 139 were randomized to LG-CC and 145 to UC. Among patients 
completing baseline assessments (N=284); the mean age was 55.2 (SD=10.9; range 28-75 years), 
15.6% were women, the majority (62%) were diagnosed with depression, and the majority (63%) 
were diagnosed with hypertension or were overweight (BMI mean±SD=33.3±6.3). Baseline 
VR-12 physical health component score was below population norms (50.0±SD=10) at 33.4±11.0.
Conclusions—Findings from this trial may inform initiatives to improve physical health for 
SMI patient populations.
Keywords
care management; self-management; mood disorders; schizophrenia
INTRODUCTION
Serious mental illness (SMI-including schizophrenia, bipolar disorder, and recurrent major 
depressive disorder)1 is associated with substantial functional impairment, morbidity, 
economic burden, and mortality [1-3]. Persons with SMI receiving care die on average 8-25 
years younger than the U.S. general population [1, 4], and a key driver of this premature 
mortality is increased burden from medical conditions, particularly cardiovascular disease 
(CVD) [1, 5, 6]. Some of the most common medical conditions (e.g., hypertension, 
hyperlipidemia) that disproportionately burden patients with SMI [5] are also the leading 
risk factors for CVD.
While there has been much attention concerning CVD risk factors associated with second 
generation antipsychotics, unhealthy behaviors, notably lack of physical activity, can 
1
HbA1C hemoglobin A1C
ICD-9-CM International Statistical Classification of Diseases, 9th Revision, Clinical Modification
LG-CC Life Goals Collaborative Care
MHICM mental health intensive case management
SMI serious mental illness
VR-12 Veterans short form survey
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contribute up to 60% increased CVD mortality risk in patients with SMI compared to those 
without these disorders [6]. Moreover, patients with SMI are often managed in specialty 
mental healthcare settings, and may experience gaps in quality of medical care [7] for 
services that require coordination between mental health and general medical providers [8]. 
Psychiatric symptoms can further exacerbate CVD risk. For example, mood symptoms can 
decrease motivation to seek medical care when needed and increase sedentary lifestyle, 
leading to subsequent weight gain [9]. Psychotic symptoms can also impede healthy 
behaviors and increase the risk of substance use [10].
Interventions for persons with SMI need to address multiple barriers to reduce CVD risk and 
improve outcomes by incorporating behavioral change and collaborative care strategies. 
Collaborative Care Models (CCMs) [11], which provide proactive care for patients through 
self-management education, coordination of services, and ongoing follow-up with patients 
and communications with providers by a care manager have been shown to improve medical 
and psychiatric outcomes, primarily for patients with depression [12]. More recently, Life 
Goals Collaborative Care (LG-CC), a CCM-based intervention developed to address 
physical health and CVD risk in patients with bipolar disorder, led to improved mental 
health physical health outcomes [13-16]. LG-CC adds components of health behavior 
change to the CCM components, notably by linking symptom management with healthy 
behavior goal-setting, as well as follow-up on physical and mental health symptoms and 
care. However, to date LG-CC has not been tested in a broader SMI patient population, 
including those with chronic major depression or schizophrenia, which represent the 
majority of persons seeking care in mental health outpatient clinics.
The goal of this single-blind randomized controlled trial (SMI Life Goals) is to determine 
whether LG-CC compared to usual care improves physical and mental health outcomes in 
12 months among patients with SMI. Our primary hypothesis is, within 12 months, patients 
randomized to receive LG-CC compared to those randomized to receive usual care will have 
improved physical health-related quality of life (VR-12) scores from baseline to 12 months 
later. Our secondary hypotheses are that compared to those enrolled in UC, patients in the 
LG-CC group will have reductions in CVD risk factors, notably 1) improved mental health-
related quality of life scores, 2) lower systolic blood pressure, 3) lower diastolic blood 
pressure , 4) lower body mass index (BMI), and 5) increased physical activity in 12 months. 
Exploratory outcomes include psychiatric symptoms and intermediate and long-term CVD 
risk factors.
MATERIALS and METHODS
This is a prospective, randomized, controlled, single-blind, effectiveness intervention trial 
designed to determine whether the LG-CC compared to usual care improved outcomes in 12 
months among adult patients diagnosed with serious mental illness with at least one CVD 
risk factor who received care in a large urban VA outpatient mental health clinic. Patients 
were randomized following the completion of a baseline survey and clinical assessment by 
the study outcomes assessor. LG-CC was delivered be the study interventionist (health 
specialist). The study outcomes assessor is blinded to the treatment arm the patients were 
assigned, but the interventionist (health specialist) and patients enrolled were not blinded. 
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This study received IRB approval and all patients provided informed consent. No changes to 
the trial design were made.
Setting, Recruitment, and Participants
The study is being conducted at an outpatient mental health clinic at a large Midwestern 
U.S. Department of Veterans Affairs medical center. Using VA electronic medical records, 
the study data analyst and outcomes assessor would first use the VA electronic medical 
record system to identify all potentially eligible patients based on the following inclusion 
criteria:
1. Age 18 years or older with a diagnosis of serious mental illness in the medical 
record based on the presence of at least one inpatient or outpatient ICD-9-CM [17] 
diagnosis of schizophrenia, bipolar disorder, or major depressive disorder within 
the past year from the study recruitment start date (February 15, 2010). These SMI 
ICD-9 CM diagnoses were chosen because they were considered the most chronic 
and debilitating mental health diagnoses that are primarily seen in VA mental 
health specialty [18].
2. Having at least one of the following risk factors for CVD (cardiovascular disease) 
recorded in the medical record:
a. Body mass index (BMI) >28 or waist circumference of >35 (women) or 
>40 (men) inches OR
b. Documentation of a diagnosis of or treatment for hypertension (defined as 
documented diagnosis or blood pressure of >140/90 on 2 occasions or 
prescription for an antihypertensive medication), dyslipidemia 
(documented diagnosis or LDL>160 or prescription for a lipid-lowering 
medication) or diabetes mellitus (documented diagnosis or HbA1C >7% 
or current prescription for oral hypoglycemic therapy)
All potentially eligible participants based on medical record review were then approached 
by the study outcomes assessor, who then confirmed eligibility and offered enrollment in the 
study. At the time of study enrollment, the outcomes assessor excluded potential participants 
if any of the following exclusion criteria were met:
1. Unresolved substance intoxication or withdrawal, such as appearing to be 
intoxicated (e.g., incoherent, slurred speech), or experiencing withdrawal 
symptoms from substance abuse at the time of enrollment.
2. Unwilling or unable to provide informed consent or comply with study 
requirements at the time of enrollment (e.g., unable to complete forms or attend 
sessions due to substantial functional limitations).
3. Expression of active suicidal ideation at time of enrollment
Enrollment and Randomization Procedures
Enrollment procedures included confirmation of eligibility, documentation of informed 
consent, and completion of a baseline questionnaire, and brief clinical assessment (physical 
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exam) by the study outcomes assessor. Those eligible and consenting to be in the study are 
given a baseline survey and brief clinical assessment to assess systolic and diastolic blood 
pressure, weight, and waist circumference, described in detail below.
Patients are then randomized by the study data analyst to receive LG-CC or usual care (UC; 
Table 1). Patients were randomized when at least 16 but no more than 20 patients at a time 
were recruited and enrolled into the study, in order to ensure sufficient numbers of patients 
for the intervention group sessions and avoid delays between the baseline assessment and 
intervention initiation. Randomization was stratified by gender, age, race, and presence/
absence of diabetes diagnosis. Participants received $20 gift card as remuneration at each 
outcome assessment wave.
LG-CC Intervention
Patients randomized to receive Life Goals Collaborative Care (LG-CC) are then contacted 
by the health specialist to conduct an initial assessment, and then are scheduled for group 
self-management sessions. In addition to the self-management sessions patients randomized 
to receive LG-CC also receive care management, and their principle primary care and 
mental health providers also receive support from the health specialist (Table 1). LG-CC is 
based on the Collaborative Care Model that was customized to address unique barriers to 
optimal medical outcomes, particularly around CVD risk factors, faced by persons with SMI 
(Figure 1) [19].
Interventionist training and background—The health specialist is responsible for 
direct encounters for each of the LG-CC components described below, including group 
sessions, post-group follow-up phone contacts, and communications with providers. The 
health specialist has a master’s in health education and a background in mental health care 
and mental health psychoeducation. The Health Specialist was trained by the Study PI, Co-
Investigators, as well as a Life Goals training specialist. The health specialist training 
program was developed from prior LG-CC studies [13-16] and was customized by study co-
investigators to address broader symptom issues related to SMI. The health specialist 
training consisted of a 2-day course that included: 1) background on the LG program, review 
of the program’s clinical evidence, and overview of the three components (self-management, 
care management, and provider support) (Day 1), and 2) role plays to practice the specific 
components and training across SMI diagnoses (Day 2). The health specialist also has access 
to a hardcopy of the intervention manual as well as access to all handouts in electronic 
format and hardcopy for group sessions
Self-management—The LG-CC self-management component includes five separate 
group weekly sessions delivered by the health specialist in a guided, semi-structured format 
that last approximately 90 minutes each that were focused on reducing psychiatric 
symptoms by promoting healthy behaviors. Derived from social cognitive theory [20] and 
health belief model [21], the central tenet of the LG-CC self-management program is 
reducing both CVD risk factors and psychiatric symptom burden through the use of healthy 
behavior change goal-setting through increased physical activity and healthier eating choices 
[22, 23]. Specifically, the self-management program assumes patients make decisions about 
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behavior change based on their own analysis of potential costs and benefits [24] , and the 
health specialist, using motivational enhancement techniques, helps them build self-efficacy 
for change [25]. Through ongoing monitoring, the health specialist also promotes 
maintenance to the health behavior changes as well as provider engagement to reinforce 
behavior change [16]. Where appropriate, the health specialist also provides patients 
information on community organizations or groups that support health behavior change or 
recovery (e.g., 12-step addiction groups).
Care management—LG-CC care management includes six monthly contacts lasting 
approximately 20 minutes made to each patient by the health specialist that are tracked using 
a Microsoft Access registry. The purpose of the care manager calls is to discuss progress on 
achieving health behavior goals (physical activity, dietary changes) that were selected by 
patients in the self-management sessions, as well as to monitor health status and disseminate 
information on linkages to community resources where appropriate (Table 1). The health 
specialist also contacts the patient’s primary care and mental health providers each month. 
These provider contacts are made either through the VA electronic medical record in the 
form of a view alert sent to the provider about a specific patient, or in person if the provider 
is available.
The health specialist uses the registry primarily to record contacts from the care 
management component of LG-CC, but also to record information from the initial contact 
made to patients prior to scheduling the self-management sessions (e.g., to record principle 
care providers for future contact), and during the self-management sessions to record 
patient-specific health behavior goals. The registry tracks patients’ health behavior change 
progress (e.g., progress on physical activity or dietary changes), ongoing medical and 
psychiatric symptoms, and current treatments (e.g., medications, health status, and if 
applicable, no-shows and rescheduled appointments for reminder purposes). The health 
specialist uses this information to relay any potential health concerns to patients’ primary 
care and/or mental health providers, especially if symptoms were not improving or there is a 
need to follow up on other treatment issues (e.g., medication refills, new symptoms 
requiring attention). As the registry is customized to help track clinical care related to LG-
CC, it is not embedded in the VA electronic medical record system and providers do not 
have access to this registry.
Provider support—In addition to the regular contacts with the providers, the health 
specialist also disseminates a care plan that includes patients’ health status and behavior 
goals to their primary care and mental health providers after the last care management 
contact. The goal of this care plan is to facilitate provider decision-making regarding 
ongoing clinical management by their assigned primary care and mental health provider 
once the LG-CC program is over. The health specialist also disseminates at staff meetings 
on a quarterly basis summaries of the LG-CC program as well as the VA guidelines for 
CVD risk factor monitoring, which cover cardiometabolic assessments recommended for 
individuals prescribed atypical antipsychotic medications. [26]
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LG-CC Fidelity Monitoring
Fidelity to patient receipt of LG-CC components include observations of 50% of groups and 
monitoring of patient and provider contacts based on the registry. Adequate fidelity to LG-
CC will be defined as: mean percentage of self-management sessions attended by patients is 
≥80% (average of 4 out of 5 sessions attended), mean percentage of session topics covered 
in lessons is ≥80%, and mean percentage of completed number of care management contacts 
to patients is ≥65% (mean number of 4 out of 6 required contacts).
Usual Care
Patients randomized to the usual care group receive their routine VA care (Table 1), but 
there are no ongoing contacts by the health specialist to patients or their providers or any 
registry tracking provided. Usual care in the mental health clinic includes on-site 
psychiatrists who provide routine medication management, as well as psychologists and 
social workers who provide individual or group psychotherapy sessions on an ad-hoc basis 
for specific diagnosis (e.g., PTSD) or treatment modalities (e.g., cognitive behavioral 
therapy). However, the psychotherapy sessions do not provide specific guidance in 
managing psychiatric symptoms or their relationship to CVD risk factors. Case management 
is also available in the mental health clinic. Routine medical care is provided by general 
practitioners who resided on a different floor of the same facility, both without any contacts 
or information on patient care preferences or needs by the health specialist.
Outcomes
Patient outcome assessments include a self-completed survey and a clinical exam 
administered at baseline, six, and twelve months later by the outcomes assessor. The survey 
includes questions for the primary, secondary, and exploratory outcomes (quality of life, 
symptoms, and health behaviors), as well as covariates. The clinical exam was completed in-
person in a private room in the mental health clinic and includes clinical measures for 
secondary and exploratory outcomes related to CVD risk. Additional CVD risk factors (e.g., 
lab values) and covariates (e.g., medical diagnoses) are ascertained from the VA electronic 
medical record.
Primary Outcome Measure—The primary outcome is changes in physical health-related 
quality of life between baseline and 12 months later. This outcome was chosen because 
physical health-related quality of life is thought to be directly affected by the LG-CC 
intervention based on prior studies [15, 16] [22, 23], regardless of mental health diagnosis or 
specific CVD risk factors. Self-reported poor physical HRQOL was also shown to be 
significantly associated with a 2 to 3-fold increased risk in CVD-related mortality 
[28].Physical health-related quality of life is assessed using the patient survey based on the 
Veterans Short-Form (VR)-12 [27]. The VR-12 is a widely used and validated instrument 
that generates two composite scores: physical health (PCS) and mental health (MCS) 
composite scores. Both the PCS and MCS were scored 0-100 (higher scores represent better 
health-related quality of life) and normalized so that 50 ±10 represented the mean ± standard 
deviation for the general population.
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Secondary Outcomes—The five secondary (exploratory) outcomes include 1) mental 
health-related quality of life based on the aforementioned MCS score, 2) systolic blood 
pressure, 3) diastolic blood pressure, 4) body mass index (BMI), and 5) physical activity; 
variables though to directly affect CVD risk [15, 16]. Blood pressure is ascertained from a 
clinical exam that included averaging the two separate readings of the patients’ blood 
pressure sitting down. BMI is assessed during the same clinical exam by measuring the 
patients’ weight and recording height from the medical record. Physical activity is assessed 
via the patient survey using the Physical Activity Questionnaire-Short Form (IPAQ-SF), a 
self-reported four-item measure of habitual physical activity over the past 7 days. IPAQ-SF 
ascertains information on time spent walking in moderate intensity, in vigorous-intensity, 
and sitting, on weekdays and weekend days. An average number of minutes of activity is 
generated and multiplied by body weight and a caloric value (based on intensity) to yield 
total energy expenditure using a standard protocol (http://www.ipaq.ki.se/ipaq.htm). The 
IPAQ-SF has good reliability and validity in large population-based surveys and among 
mental health populations [29].
Exploratory Outcomes—Additional exploratory outcomes to be assessed in this study 
include psychiatric symptoms and intermediate and long-term (10-year) CVD risk factors 
[30]. Psychiatric symptoms are ascertained from the patient survey and include mood and 
psychotic symptoms, considered the most common symptoms experienced among persons 
with SMI [31]. Mood symptoms are assessed using the Patient Health Questionnaire 
(PHQ-9) and the Internal State Scale (ISS). The PHQ-9 is a previously validated measures 
for depressive symptoms used across chronically ill patient populations [32]. The ISS is an 
8-item brief self-reported symptom assessment that assesses activation (mania) and well-
being, and was strongly correlated with clinician ratings of mania [33, 34]. Psychotic 
symptoms are assessed using the 5-item revised Behavior Symptom Identification Scale 
(BASIS©)[35], a self-reported scale that assesses relationship difficulty, self-harm, and 
emotions.
Intermediate CVD risk factors include waist circumference, assessed via the clinical exam at 
baseline, six, and twelve months. In addition, long-term CVD risk factors will be assessed 
based on the Framingham Risk Score [36]. The Framingham Score is designed to estimate 
10-year risk of acquiring CVD based on a weighted score, and will be derived from key 
CVD risk factors from the clinical exam (blood pressure), electronic medical records 
(diabetes diagnosis, lipid levels), and patient survey (age, sex, and current smoking status). 
Lipid levels including fasting total cholesterol, low-density lipoprotein, and high-density 
lipoprotein in mg/dL are ascertained from the electronic medical record review using lab 
results recorded nearest to the patient’s assessment dates at baseline, 6 and 12 months.
Covariates—Covariates that might influence LG-CC response and outcomes are also 
ascertained, including demographics [13] and clinical factors from the patient survey and 
medical record review, including substance use, medical, and psychiatric comorbidities [37]. 
Substance use included self-reported alcohol use based on the Alcohol Use Disorders 
Identification Test [38, 39] as well as smoking status. Medical comorbidity diagnoses and 
Kilbourne et al. Page 8
Contemp Clin Trials. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
medications were ascertained from the medical records [37, 40] using a previously 
established chart review tool [41, 42].
Assessment and management of suicidal ideation
Once enrolled, suicidal ideation is ascertained from survey responses, and whether patients 
articular at any time thoughts of suicide or death during LG-CC sessions or contacts. During 
the baseline assessment, suicidal ideation is ascertained based on responses to one of two 
questions from the baseline and follow-up surveys: 1) “thoughts that you would be better off 
dead or of hurting yourself in some way” (several days more frequently) from the PHQ-9, or 
2) “think about ending your life” (at least sometimes) from the BASIS© [35] psychosis 
symptom assessment. If patients answer in the affirmative to one of those two questions, or 
articulate suicidal ideation at the time of enrollment or assessment or during any of the 
group sessions or contacts, study staff members (outcomes assessor, health specialist) 
employ a procedure developed with Study Investigators and the VA mental health staff that 
involves asking patients additional questions about the suicidal ideation, including whether 
there is an active plan. If patients respond in the affirmative to these follow-up questions, 
then the patient will be immediately referred to their mental health clinician, or if the 
clinician was not available, the VA Suicide Prevention Coordinator if the encounter was in 
person. If the encounter was over the phone, then the study staff member will keep them on 
the line and made a direct referral to either a crisis line or emergency room, and would 
follow up with the patient’s mental health provider to develop a suicide prevention plan 
when appropriate.
Analyses Plans
Bivariate baseline analyses will first be conducted to see if randomization was successful by 
comparing patient demographics, clinical covariates, and baseline outcome values between 
randomization groups. If there is a lack of equal distribution across groups, we will adjust 
for the imbalance by adding these baseline variables as covariates to our outcomes analyses 
or use propensity scoring. We will compare baseline characteristics and time-varying 
measures among those enrolled but dropped out over time to those who remained in the 
study. Missing data will be addressed using multiple imputation methods, where each 
missing value is replaced with a set of plausible values generated from the non-missing data.
The primary and secondary outcome variables (health-related quality of life, blood pressure, 
BMI, and psychiatric symptoms) will be treated as continuous variables, and analyses will 
focus on changes over the 6- and 12-month period between LG-CC and usual care groups in 
each outcome. For continuous outcome variables, mixed-effects models will be run to assess 
the intervention effects. An intent-to-treat analysis will be performed for all analyses, 
adjusting for all baseline covariates in the stratified randomization. A subgroup analysis by 
psychiatric diagnosis will be conducted in order to explore whether the effect of LG-CC 
versus UC varied by specific diagnosis (major depression, bipolar disorder, schizophrenia).
Sample Size
The sample size for this study was determined based on the comparison of LG-CC vs UC 
for the primary outcome: physical health-related quality of life score based on the VR-12. 
Kilbourne et al. Page 9
Contemp Clin Trials. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Specifically, the calculation was based on a small to moderate effect size for changes in the 
physical health VR-12 component score (e.g., Cohen’s D =.31) between baseline and 12 
months later comparing the LG-CC and UC groups [15, 16]. Participant refusal rates were 
anticipated to be 5% and long-term attrition rates are expected to be 10% based on similar 
studies of the LG-CC intervention in patients with bipolar disorder [15]. Sample size was 
determined by estimating the smallest detectable difference in physical health-related quality 
of life score between the population mean over time, at a significance level of .05 (using a 
two-tailed statistical test) and a minimum power of .80. Hence, recruitment called for 
enrolling 300 subjects in total in order to have at least 240 subjects complete the study 
which would account for a 20% attrition rate, assuming 0.5 within-person correlation 
coefficient, and adjustment for multiple comparisons.
RESULTS
Participants
Study staff began recruiting and enrolling patients on February 24, 2010 and all baseline 
assessments were completed by February 15, 2014 (See Figure 2 for the Consort diagram 
describing recruitment flow and losses/exclusions). Out of the 3,732 eligible patients 
screened for study participation, 2,897 were not approached due to ineligibility or inability 
to contact. Of the 835 approached, 304 were enrolled, or which 20 dropped out prior to 
randomization, resulting in a final sample size of 284. Overall, 139 were randomized to LG-
CC and 145 to usual care.
The total caseload provided by the health specialist was 139 patients over the 2-year 
enrollment and intervention period. This caseload is comparable to prior studies of LG-CC, 
in which the yearly caseload for a full-time health specialist ranged from 60-80 patients per 
year [13-16].
Baseline data
Of the 284 participants who began the study, 139 were randomized to receive LG-CC group 
and 145 to UC. The mean age was 55.2 (SD=10.9; range 28-75 years), 15.6 were women, 
17.5% were Black, reflecting similar demographics in this VA mental health clinic (mean 
age = 55, 6% female, 11% African-American). Among participants, the majority (62%) 
were diagnosed with depression (Table 3).
At baseline, VR-12 scores were markedly below population norms (50.0±SD=10) for both 
physical and mental health-related quality of life (respectively mean±SD = 33.4±11.0 and 
34.3±11.9). The majority had a diagnosis of hypertension and the mean BMI was 33.3 
(SD=6.3). In addition, the majority had a moderate to high 10-year risk for an acute 
cardiovascular event according to Framingham Risk Scores. Self-reported measures 
revealed substantial burden of depressive symptoms as well (Table 4).
There were no significant differences in baseline demographic/clinical factors or baseline 
primary or secondary outcome measures with the exception of BMI (Table 4). By chance 
alone, it is expected that at least 1-2 differences will be significant at the 5% level (1.8 = 
0.05 × 36 comparisons in Tables 3 and 4). To be conservative, however, sensitivity analyses 
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for the primary and secondary outcomes will adjust for BMI; results will be reported with 
and without adjustment.
DISCUSSION
We described the design, rationale, and baseline results of a randomized controlled trial that 
seeks to determine whether a Collaborative Care Model (LG-CC) tailored for individuals 
with SMI improves physical and mental health outcomes, notably health-related quality of 
life and CVD risk factor control. Despite ongoing access to medical care experienced by this 
VA patient cohort, a substantial number had elevated risk factors for CVD, notably 
hypertension and high BMI, which can also impact overall health. Moreover, health-related 
quality of life scores were substantially lower than the general U.S. population, reflecting a 
particularly vulnerable group.
Interventions to date that are designed to reduce CVD risk factors in persons with SMI have 
typically involved multiple provider teams [43-46], closely supervised diet or exercise 
regimens [47, 48], or were limited to a single diagnosis, thus precluding their potential 
generalizability in routine care settings [49, 50]. In contrast, LG-CC includes components 
that can be potentially taught to existing providers via a manual and training program. 
Moreover, LG-CC provides support in coping with mental health as well as physical health 
symptoms (beyond CVD risk factors), thus having the potential for increased 
generalizability by impacting overall health status. In addition, LG-CC emphasizes self-
management, care coordination, and setting personal goals, providing patients with a 
number of tools to potentially reduce CVD risk factors that extend outside the clinic walls.
The SMI Life Goals study has several strengths, notably the use of a randomized design and 
clinical exams to assess outcomes. Nonetheless, this study is not without limits. First, it is 
possible that LG-CC could be less effective for VA patients with psychotic disorders, such 
as schizophrenia, which is often associated with cognitive limitations. Nonetheless, there is 
growing realization that similar psychosocial programs such as cognitive-behavioral therapy 
can be delivered effectively for patients with schizophrenia [51]. This study will closely 
track program adherence as well as changes in key outcomes stratified by patient diagnosis 
to determine whether further adaptations to LG-CC are necessary. Second, key components 
of LG-CC are currently not integrated with existing VA services, notably the patient registry 
with the VA electronic medical record or the group self-management sessions in the mental 
health clinic.
The additional time involved in implementing LG-CC self-management group sessions, care 
management, and follow-up with providers would be challenging for one person to perform 
without protected clinical time. If the intervention is found to be effective, study 
investigators will plan an implementation initiative to incorporate LG-CC components into 
routine VA care, notably by identifying existing VA infrastructures (e.g., electronic medical 
record fields) and providers (e.g., social workers) that could be deliver the LG-CC 
components. Third, there is potential that the usual care group will be exposed to some of 
the LG-CC components, notably through contacts by the health specialist with providers 
who are also treating patients in the usual care group. However, LG-CC components are 
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tailored by the health specialist for patients based on their unique needs, so it is unlikely that 
the interactions between the health specialist and providers will directly impact patients in 
the usual care group. Fourth, cost considerations precluded us from including measures that 
involved direct observation of health behaviors such as physical activity. Finally, the 
generalizability of the sample is limited by the focus on a VA patient population, as VA’s 
medical and mental health services [52]. Still, the persistent level of CVD risk factors has 
been observed elsewhere in non-VA settings [53].
Despite these potential limitations, this study represents an important step forward in 
addressing an often unmet treatment need among patients with SMI regardless of their 
psychiatric diagnosis. CVD remains the number one cause of morbidity and mortality 
among persons with SMI, and despite the dissemination of guidelines to manage CVD risk 
factors [54], outcomes remain suboptimal for this group. Furthermore, Veterans are a 
vulnerable group that is characterized by lower socioeconomic status, greater medical 
morbidity, and a higher probability of having comorbid psychiatric disorders. The VA is a 
significant provider of mental health services to patients with SMI across the U.S. and thus 
results will have implications for improving care to this patient population.
Overall, the SMI Life Goals Study will potentially add to the much-needed literature on 
studies addressing medical and psychiatric needs of patients with SMI. Current baseline 
findings show that patients with SMI are burdened with multiple CVD risk factors while 
displaying a propensity for poor health behaviors and lower health-related quality of life. 
Results from this trial will inform efforts to improve health outcomes and reduce CVD risk 
for persons with SMI.
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Figure 1. 
LG-CC Components and Outcomes Related to SMI
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Figure 2. 
CONSORT: Participant Recruitment and Enrollment Flow Diagram
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Table 1
Life Goals Collaborative Care (LG-CC) and Usual Care (UC): Timeline and Core Components:
Timeline LG-CC Components Usual Care
Baseline • Baseline survey and clinical exam
• Initial contact by health specialist
• Baseline survey and clinical 
exam
• No contact by health specialist
Months 1-2 Five weekly self-management sessions by health specialist
Five group sessions (90 minutes, approx. 8-10 individuals per
group cohort) covering:
• SMI facts
• Understanding personal and behavioral risk factors for CVD
• Setting personal goals
• Active discussions of coping with psychiatric symptoms and 
strategies to manage psychiatric/ medical risks factors
• Provider engagement and communication tips
No self-management sessions or follow-
up contacts by health specialist
Months 3-8 Care management by health specialist:
• Conduct ongoing patient contacts monthly for 6 months to reinforce 
lessons from self-management, track progress on patient-specific 
physical activity and dietary goals made during self-management 
sessions, and identify symptoms or other health issues to relay to 
providers Provides links to community resources where applicable.
• Health specialist contacts patient’s principle primary care and 
mental health provider on a monthly basis using electronic medical 
record view alerts or in-person curbside consultations to relay 
potential issues brought up when contacting patients, including 
physical or mental health symptoms, medication side effects, 
symptoms, or urgent health concerns
• Health specialist uses the registry for recording information from 
initial contact made to patients prior to scheduling the self-
management sessions, during the self-management sessions, and for 
care management contacts. Uses registry to monitor contacts, patient 
progress in health behavior change, mental health symptoms, and 
care needs over time
(6 month survey and clinical exams conducted 6 months
after patient’s enrollment date)
No ongoing contacts to patients by the
health specialist or registry tracking
Standard services available in the
mental health clinic include ongoing
clinical management by patients’
assigned primary care and mental
health providers, case management,
group psychotherapy, and individual
psychotherapy on an ad-hoc basis.
(6 month survey and clinical exams
conducted 6 months after patient’s
enrollment date)
Provider support
• Health specialist provides care plan to primary care and mental 
health providers on mental health treatment and health issues after 
last care management contact to facilitate ongoing clinical 
management
• Health specialist disseminates information on LG-CC program and 
VA guidelines for CVD risk monitoring to primary care and mental 
health providers at staff meetings
No ongoing contacts to providers or
care plan provided by the health
specialist
Health specialist disseminates
information on LG-CC program and VA
guidelines for CVD risk monitoring to
primary care and mental health
providers at staff meetings
Month 12 • 12-month survey and clinical exam • 12-month survey and clinical 
exam
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Table 2
LG-CC: Summary of Self-management Session Content
Session Focus points
(core behaviors addressed)
Topics covered
Motivational
enhancement
principles used
throughout all
sessions
Interactions with patients characterized by a non-judgmental approach to elicit
change in self-management behaviors through patient interactions using opened-
ended questions, active listening, affirmations of desired behaviors and
statements, and developing discrepancy between present actions to self-manage
psychiatric and health concerns with core patient values to develop intrinsically-
based action plans for self-management.
Session 1:
Program
orientation, self-
management
• Patient perspective of collaborative care and 
provider engagement
• Establish association between mental and 
physical health
• Explain biopsychosocial model of self-care
• Values identification exercise to motivate 
health behavior goal setting
• Establish understanding of mental health 
and CVD risk factors on physical health
• Exercise: goal prioritization
• Patient-centered collaborative care
• Causes of mental health disorders; prevalence, 
stigma, behavioral comorbidity
• Psychiatric symptoms and behaviors contributing 
to CVD risk
• Impact of mental illness symptoms on functioning 
and role with physical health
• Treatments for CVD risk prevention
• Values clarification exercise
• Prioritizing areas for change
• Small change approach for health
Session 2:
Managing mental
health symptoms
• Impact of mental symptoms on personal 
functioning
• Symptom management and lifestyle change
• Exercise: personal symptom profile and +/- 
coping behaviors
• Identify triggers to psychiatric symptoms 
(e.g., substance use)
• Exercise: decisional balance of choices to 
manage symptoms
• Personal assessment of health behaviors for 
initial action plan for symptom management 
and physical health behavior change
• Recognizing psychiatric symptoms and impact on 
physical health
• Personal psychiatric symptom profile;
• Medical and behavioral consequences of 
psychiatric symptoms (overeating, sedentary 
lifestyle)
• Triggers to serious psychiatric episodes
• Proactive, positive coping plans for coping with 
psychiatric symptoms
• Cost-benefit analysis of various self-management 
strategies for psychiatric symptoms and relation to 
overall health
Session 3:
Overcoming
thoughts that get 
in
the way of 
wellness
• Recognizing how thoughts, feelings & 
perceptions affect behavior responses
• Exercise: the Observing Self
• Reflecting on thoughts and actions that 
promote positive health behaviors
• Incorporating mindfulness into managing 
health behaviors
• Reviewing the priority of health behavior 
change goals
• Recognizing how affective/psychosis symptoms 
impact perceptions of events
• Developing insight into the cognitive behavioral 
approach to symptom management
• Contingency planning and problem-solving 
environment triggers/cues to identify positive 
coping responses
• Adopting nonjudgmental reactions to stressors
• Benefits of coping with affective symptoms in the 
context of CVD risk
• Eliciting examples of small steps towards setting 
diet & exercise goals
Session 4:
Motivational
enhancement-
based wellness
goals
• Reviewing the interrelationship between 
physical & mental health
• Understanding personal risks for metabolic 
syndrome (lab values, vitals, cholesterol 
monitoring)
• Making healthy nutritional choices
• Association between nutrition and CVD risk 
factors, weight gain, impact on mental illness 
symptoms and functioning (energy, fatigue, self-
esteem)
• Components of healthy diet; portion control; 
identifying healthy foods (low fat, lower salt and 
sugar content)
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Session Focus points
(core behaviors addressed)
Topics covered
• Benefits of physical activity for mind and 
body
• Exercise for anxiety/stress reduction
• Monitoring sleep patterns
• Triggers for unhealthy eating.
• Risks of an inactive lifestyle; attaining desirable 
levels of physical activity for health; identifying 
personal and environmental barriers to activity
• Making a personal action plan for physical 
activity using small steps approach; recognizing 
safety concerns, physical limitations.
• Importance of establishing good sleep hygiene
Session 5: • Building and strengthening collaborative 
care,
• Preparation for effective visit 
communication with providers
• Anticipating barriers and facilitators to 
long-term self-management
• Understanding treatment strategies to 
manage risks
• Medication adherence (CVD)
• Identifying and linking to community 
resources.
• Relapse Prevention
• Developing a personalized wellness plan 
(diet, exercise tips)
• Preparing for small change goal follow-up 
contacts
• Optimizing patient and provider engagement at 
care visits
• Facilitating communication with medical 
providers (e.g., setting goals for blood pressure 
and cholesterol, listing personal concerns, 
discussing medication side effects)
• Reviewing psychosocial therapies
• Reviewing medication treatments
• Identifying community and personal resources for 
long-term change
• Personal care planning; treatment adherence: 
problem solving strategies and contingency 
planning to overcome relapses to wellness and 
mental health goals
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Table 3
Participant Demographic and Clinical Characteristics
Total
(N =284)
LG-CC
(N=139)
Usual care
(N =145)
mean±sd
or
median (IQR)
%
mean±sd
or
median
(IQR)
%
mean±sd
or
median
(IQR)
% t p-
value
Demographics
Age;Range:28-75 yrs 55.2 ± 10.9 55.1±10.7 55.3 ± 11.0 −.13 .90
 Age breakdown
  <50 years 26.0 24.6 27.3 .87
  50-59 years 31.7 32.6 30.8
  ≥ 60 years 42.4 42.8 42.0
 Female 15.6 15.8 15.4 .92
 Black (vs. non-Black) 17.5 20.9 14.3 .15
 Some college education 29.1 32.4 25.9 .23
 Lives alone 32.2 30.0 34.3 .45
Clinical Factors
Current SMI Diagnosisa
 Schizophrenia 7.0 5.0 9.0
 Bipolar disorder 24.3 23.7 24.8
 Major depression 57.4 60.4 54.5 .56
 Other SMI 11.3 10.8 11.7
Current Substance Use
 Current Smoker 25.7 22.3 28.8 .22
 Alcohol misuse
   AUDIT-C Scoreb 0 (0,2) 0 (0,2) 0 (0,2) .77
   % Hazardous Drinkingc 12.1 11.2 13.0 .66
Current CVD Diagnosisd
 Hypertension 63.7 64.8 62.8 .73
 Hyperlipidemia 61.6 61.9 61.4 .93
 Diabetes mellitus 31.0 33.1 29.0 .45
Medicationse
 Antipsychotics 38.0 33.1 42.8 .09
 Antidepressants 83.5 85.6 81.4 .34
 Mood Stabilizers 52.1 49.6 55.5 .41
Statistical method: Chi-squared test for categorical variables (% reported); Two independent samples t-test for numeric variables (mean±sd 
reported); Wilcoxon-Mann-Whitney test for the variables with a highly skewed distribution (median (IQR) reported).
aSMI diagnosis based on medical record review and confirmed by patients’ mental health care professional
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bAUDIT-C scores are defined on 0-12 scale and based on 3 items with higher scores indicating more serious drinking. Wilcoxon-Mann-Whitney 
test is used for this variable.
cCurrent hazardous drinking is based on the score of one item of AUDIT-C defined as having 6 or more drinks on one occasion in the past month 
(yes/no).
dCVD-related diagnoses based on medical record review
e
Medication use ascertained from the medical record include any current use of antipsychotic medications, antidepressants, or mood stabilizing 
medications
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Table 4
Baseline Assessment Results of Participants: Primary and Secondary Outcomes
Total
(N =284)
LG-CC
(N=139)
Usual care
(N =145)
mean ± sd
or
median (IQR)
%
mean ± sd
or
median (IQR)
%
mean ± sd
or
median (IQR)
% t p-
value
Primary outcome
HRQOL physical health 33.4 ± 11.0 32.8 ± 10.9 33.9 ± 11.0 −.92 .36
Score (VR-12)a
Secondary outcomes
HRQOL mental health 34.3 ± 11.9 35.2 ± 12.2 33.4 ± 11.6 .20
Score (VR-12)a 1.30
Systolic BP, mmHgb 135.4 ± 14.4 135.8 ± 14.5 135.1 ± 14.4 .44 .66
Diastolic BP, mmHgb 77.5 ± 9.8 76.9 ± 9.7 78.0 ± 9.9 −.88 .38
BMI, kg/m2c 33.3 ± 6.3 34.3 ± 7.11 32.3 ± 5.2 2.66 .008
 <25 5.3 5.0 5.5
 25-29.9 27.5 25.9 29.0
 30-34.9 31.7 29.5 33.8
 35-39.9 21.5 19.4 23.5
 ≥40 14.1 20.1 8.3 .08
Physical activity (min/wk)d 113.8 ± 159.0 104.3 ± 141.5 123.7 ± 175.5 −.87 .39
  Walking (min/wk) 82.0 ± 134.8 70.8 ± 125.7 92.8 ± 142.8 −1.24 .22
  Moderate (min/wk) 18.4 ± 44.4 19.7 ± 46.6 17.1 ± 42.3 .43 .66
  Vigorous (min/wk) 15.6 ± 42.6 15.8 ± 43.4 15.3 ± 42.1 .09 .93
Exploratory outcomes
Psychiatric Symptoms
 Depression: PHQ-9e 12.0 ± 5.9 11.6 ± 5.7 12.4 ± 6.0 −1.17 .24
   <10 36.0 39.9 32.4 .42
   10-14 38.2 35.5 40.7
   >=15 25.8 24.6 26.9
 Psychosisf .8 (.1, 1.7) .7 (.0, 1.5) .8 (.1, 1.8) .23
 Manic (activation) g 20.4 ± 11.1 19.8 ± 11.1 20.9 ± 11.2 −.82 .41
 Well-beingg 16.5 ± 6.7 16.5 ± 6.7 16.4 ± 6.7 .02 .99
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Total
(N =284)
LG-CC
(N=139)
Usual care
(N =145)
mean ± sd
or
median (IQR)
%
mean ± sd
or
median (IQR)
%
mean ± sd
or
median (IQR)
% t p-
value
Framingham (FH) Scoreh 12.4 ± 7.6 12.4 ± 7.4 12.3 ± 7.9 .87 .39
 FH < 10% 36.3 36.2 36.3
 FH 10-20% 55.0 55.1 54.8
 FH > 20% 8.8 8.7 8.9 .99
Waist Circumference, in. i 45.2 ± 6.1 45.9 ± 6.1 44.4 ± 5.4 2.0 .04
Statistical method: Chi-squared test for categorical variables (% reported); Two independent samples t-test for numeric variables (mean±sd 
reported); Wilcoxon-Mann-Whitney test for the variables with a highly skewed distribution (median (IQR) reported).
a
Health-related quality of life (HRQOL) was assessed from the patient survey using the 12-item Veterans Short-Form Health Survey (VR-12). 
Mental health (MCS) and physical health (PCS) component scores each ranged from 0 to 100, with higher scores indicating better health.
bSystolic and diastolic blood pressure were ascertained from a clinical assessment: based on the average of two blood pressure readings sitting 
down
c
Height and weight measurements to calculate body mass index (BMI) were ascertained from medical records and the clinical assessment, 
respectively
d
Physical activity was assessed via the International Physical Activity Questionnaire (IPAQ), which defines physical activity in # minutes per week 
based on 7-day self-report.
e
The Patient Health Questionnaire (PHQ-9) depression symptom scale is a 9-item measure scored 0 to 27, with higher scores indicating more 
depressive symptoms. Scores <10 represent minimal symptoms, 10–14: dysthymia or mild depression, and >=15: moderate-severe depressive 
symptoms.
f
Psychosis was assessed using a 5-item subscale of BASIS® measure; as a weighted sum of 4 items (scores range from 0-4), with a higher score 
indicating more severe symptoms. Wilcoxon-Mann-Whitney test is used for this variable.
g
Manic and well-being symptoms were assessed using the Internal State Scale (ISS), which includes scales for manic symptoms (scores range from 
0 to 50, with higher score indicating more severe manic symptoms) and well-being (scores range from 0 to 30, with higher scores indicating great 
well-being).
h
Framingham Risk Scores: 3 risk categories estimate 10-year risk for coronary heart disease: high risk (>20%), moderately high risk (10%-20%), 
or lower to moderate risk (10-year risk <10%)
iWaist circumference was ascertained from the patient clinical assessment
Contemp Clin Trials. Author manuscript; available in PMC 2015 September 01.
